TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
Therapeutic antibodies that block the programmed death-1 (PD-1)–programmed death-ligand 1 (PD-L1) pathway can induce robust and durable responses in patients with various cancer...